Clostridioides difficile

Clostridioides difficile
Name	Clostridioides difficile
Synonyms	Clostridium difficile, C. diff
Field	Infectious diseases, Gastroenterology
Symptoms	Watery diarrhea, fever, abdominal pain
Complications	Pseudomembranous colitis, toxic megacolon, sepsis
Causes	Infection by Clostridioides difficile bacteria
Risks	Antibiotic use, hospitalization, advanced age
Diagnosis	Stool testing for toxin or GDH
Treatment	Antibiotics (e.g., vancomycin, fidaxomicin), fecal microbiota transplant
Prevention	Contact precautions, antimicrobial stewardship

Clostridioides difficile is a Gram-positive, spore-forming bacterium that is a leading cause of healthcare-associated diarrhea worldwide. Infection, often termed C. difficile infection (CDI), ranges from asymptomatic colonization to severe, life-threatening colitis. The organism's resilience and ability to produce potent toxins make it a significant challenge in modern medicine, particularly within hospitals and long-term care facilities.

Microbiology and taxonomy

The bacterium was first isolated in 1935 by Hall and O'Toole from the stool of healthy infants and was originally named Bacillus difficilis due to its difficulty in culture. It was later reclassified into the genus Clostridium. Following detailed phylogenetic analysis using 16S ribosomal RNA gene sequencing, it was moved to the new genus Clostridioides in 2016. It is an obligate anaerobe, requiring the absence of oxygen to grow, and forms endospores that are highly resistant to heat, disinfectants, and antibiotics, allowing for prolonged environmental survival. The bacterium's genome has been extensively studied, with notable hypervirulent strains like NAP1/BI/027 identified through techniques like pulsed-field gel electrophoresis.

Pathogenesis and virulence factors

Pathogenesis begins when the hardy spores are ingested and survive the acidic environment of the stomach, germinating into vegetative cells in the colon. Disease primarily occurs when the normal gut microbiota is disrupted, typically by antibiotics, allowing C. difficile to proliferate. The main virulence factors are two large exotoxins: Toxin A (TcdA) and Toxin B (TcdB). These toxins glycosylate and inactivate host Rho GTPases, leading to cytoskeletal disruption, loss of epithelial barrier function, apoptosis, and a profound inflammatory response. Some epidemic strains also produce a binary toxin (CDT), which may enhance virulence and disease severity.

Epidemiology and risk factors

C. difficile is a major cause of nosocomial infections in developed nations like the United States and those in the European Union. The primary risk factor is exposure to antimicrobial agents, especially broad-spectrum antibiotics like clindamycin, fluoroquinolones, and cephalosporins. Other significant risks include advanced age, prolonged hospitalization, residence in a nursing home, severe underlying illness, and use of proton pump inhibitors. The emergence of the hypervirulent NAP1/BI/027 strain in the early 2000s, associated with increased morbidity and mortality, marked a significant shift in epidemiology. Community-associated cases are also increasingly recognized.

Clinical presentation and diagnosis

Clinical manifestations range from mild, self-limiting diarrhea to fulminant colitis. Symptoms often include watery diarrhea, lower abdominal cramping, low-grade fever, and leukocytosis. Severe complications can include pseudomembranous colitis, visible on sigmoidoscopy or colonoscopy as yellow-white plaques on the colonic mucosa, and life-threatening toxic megacolon or bowel perforation. Diagnosis relies on laboratory testing of stool samples. Common methods include nucleic acid amplification tests (NAATs) to detect toxin genes, enzyme immunoassays for Glutamate dehydrogenase (GDH) antigen and toxins, and the highly specific but slower cell cytotoxicity neutralization assay.

Treatment and management

First-line treatment involves discontinuing the inciting antibiotic if possible. For an initial non-severe episode, guidelines from the Infectious Diseases Society of America recommend oral vancomycin or fidaxomicin. Metronidazole is now reserved for non-severe cases only when other agents are unavailable. For first recurrence or severe infection, a prolonged, tapered course of vancomycin is often used. For multiple recurrences, fecal microbiota transplant (FMT) has shown high efficacy in restoring a healthy microbiome and preventing relapse. Severe, complicated disease may require intravenous metronidazole combined with high-dose oral vancomycin, and surgical consultation for possible colectomy.

Prevention and control

Infection prevention in healthcare settings is paramount and relies on strict contact precautions, including the use of gowns and gloves, and placement of patients in private rooms. Meticulous environmental cleaning with sporicidal agents like hypochlorite-based solutions is essential to eliminate spores. Robust antimicrobial stewardship programs to reduce inappropriate antibiotic use are a critical preventive strategy. Other measures include hand hygiene with soap and water, as alcohol-based hand sanitizers are ineffective against spores, and the potential use of probiotics in high-risk patients, though evidence is mixed. Vaccine development targeting the toxins is an active area of research.

Category:Infectious diseases Category:Bacteria Category:Medical microbiology